Læknablaðið - 15.02.1996, Blaðsíða 28

136
LÆKNABLAÐIÐ 1996; 82
4. Sigfússon Á, Guðmundsdóttir Ó. Af flæðifrumusjám.
Blað meinatækna 1991; 1: 3—11.
5. Headley DW, Friedlander ML, Taylor IW, Rugg CA,
Musgrove EA. Method for analysis of cellular DNA
content of paraffin-embedded pathological material us-
ing flow cytometry. J Histochem Cytochem 1983; 31:
1333-5.
6. Erhard K, Auer G. Mammary carcinoma: comparison
of DNA-content in the primary tumor and the corre-
sponding axillary lymph node metastases. Acta Path
Microbiol Immunol, Scand Sect A 1986; 95: 29-34.
7. Guðmundsdóttir G. Samanburður á DNA-innihaldi
frumæxla og meinvarpa mældu með flæðigreini. 4. árs
verkefni við læknadeild Háskóla íslands, 1994.
8. Clark GM, Dressler LG, Owens MA, Pounds G, Oldak-
er T, McGuire WL. Prediction of relapse or survival in
patients with node-negative breast cancer by DNA flow
cytometry. New Engl J Med 1989; 320: 627-33.
9. Sigurðsson H, Baldetorp B, Borg Á, Dalberg M, Femö
M, Killander D, et al. Indicators of prognosis in node-
negtive breast cancer. New Engl J Med 1990; 322:1045-53.
10. Witzig TE, Ingle JN, Cha SS, Schaid DJ, Tabery RL,
Wold LE, et al. DNA ploidy and the percentage of cells
in S-phase as prognostic factors for women with lymph
node negative breast cancer. Cancer 1994; 74: 1752-61.
11. Coulson PB, Thornthwaite JT, Woolley TW, Sugar-
baker EV, Seckinger D. Prognostic indicators including
DNA histogram type, receptor content, and staging re-
lated to human breast cancer patient survival. Cancer
Research 1984; 44: 4187-96.
12. Headley DW, Rugg CA, Gelber RD. Association of
DNA index and S-phase fraction with prognosis of
nodes positive early breast cancer. Cancer Research
1987; 47: 4729-35.
13. Kallioniemi O-P, Blanco G, Alavaikko M, Hietanen T,
Mattila J, Lauslahti K, et al. Improving the prognostic
value of DNA flow cytometry in breast cancer by com-
bining DNA index and S-phase fraction. Cancer 1988;
62: 2183-90.
14. Guðlaugsdóttir S, Sigurðsson H, Agnarsson BA, Jónasson
JG, Kristjánsdóttir S, Baldursson G, et al. DNA flæði-
greining eykur nákvæmni við mat á horfum sjúklinga með
brjóstakrabbamein. Læknablaðið 1996; 82: 138-47.
15. Headley DW, Clark GM. Cornelisse CJ, Killander D,
Kute T, Merkel D. Concensus review of the clinical
utility of DNA cytometry in carcinoma of the breast.
Cytometry 1993; 14: 482-5.
16. Briffod M, Spyratos F, Tubiana-Hulin M, Pallud C,
Mayras C, Filleul A, et al. Sequential cytopunctures
during preoperative chemotherapy for primary breast
cancer. Cancer 1989; 63 : 631-7.
17. Tribukait B, Gustafson H, Espositi P-L. The signif-
icance of ploidy and proliferation in the clinical and
biological evaluation of bladder tumours: a study of 100
untreated cases. Br J Urol 1982; 54: 130-5.
18. Lopez-Beltran A, Croghan GA, Croghan I, Matilla A,
Gaeta JF. Prognostic factors in bladder cancer. A path-
ologic, immunohistochemical, and DNA flow-cytomet-
ric study. Am J Clin Pathol 1994; 102: 109-14.
19. Klein FA, Herr HW, Sogani PC, Whitmore WF, Me-
lamed MR. Detection and follow-up of carcinomas of
the urinary bladder by flow cytometry. Cancer 1982; 50:
389-95.
20. Koss LG. The puzzle of prostatic carcinoma. Mayo Clin
Proc 1988; 63: 193-7.
21. Winkler HZ, Rainwater LM, Myers RP, Farrow GM,
Therneau TM, Zincke H, et al. Stage D1 prostatic ade-
nocarcinoma: significance of nuclear DNA ploidy pat-
terns studies by flow cytometry. Mayo Clin Proc 1988;
63: 103-12.
22. Lieber MM, Murtaugh PA, Farrow GM, Myers RP.
Blute ML. DNA ploidy and surgically treated prostate
cancer. Important independent association with progno-
sis for patients with prostate carcinoma treated by rad-
ical prostatectomy. Cancer 1995; 75: 1935-43.
23. Kallioniemi O-P, Punnonen R, Mattila J, Lehtinen M,
Koivula T. Prognostic significance of DNA index, mul-
tiploidy and S-phase fraction in ovarian cancer. Cancer
1988; 61: 334-9.
24. Friedlander ML, Russell P. Taylor IW, Hedley DW,
Tattersall MHN. Flow cytometric analysis of cellular
DNA content as an adjunct to the diagnosis of ovarian
tumours of borderline malignancy. Pathology 1984; 16:
301-6.
25. Tan LK, Flynn SD, Carcangiu ML. Ovarian serous bor-
derline tumors with lymph node involvement. Clinico-
pathologic and DNA content study of seven cases and
review of the literature. Am J Surg Pathol 1994; 18:
904-12.
26. Iversen OE. Flow cytometric deoxyribonucleic acid in-
dex: a prognostic factor in endometrial carcinoma. Am J
Obstet Gynecol 1986; 155: 770-6.
27. Britton LC, Wilson TO, Gaffey TA, Cha SS, Samuel
Wieand H, Podratz KC. DNA ploidy in endometrial
carcinoma: major objective factor. Mayo Clin Proc 1990;
65: 643.
28. Coon JS, Landay AL, Weinstein RS. Advances in flow
cytometry for diagnostic pathology. Lab Invest 1987; 57:
453-79.
29. Kokal W, Sheibani K, Terz J, Harada JR. Tumor DNA
content in the prognosis of colorectal carcinoma. JAMA
1986; 255: 3123-7.
30. Armitage NC, Robins RA, Evans DF, Turner DR,
Baldwin RW, Hardcastle JD. The influence of tumor
cell DNA abnormalities on survival in colorectal cancer.
Br J Surg 1985; 72: 828-30.
31. Melamed MR, Enker WE, Banner P, Janov AJ, Kessler
G, Darzynkiewicz Z. Flow cytometry of colorectal carci-
noma with three-year follow-up. Dis Colon Rectum
1986; 29: 184-6.
32. Lanza G Jr, Maestri I, Ballotta MR. Dubini A, Cavazzi-
ni L. Relationship of nuclear DNA content to clinico-
pathologic features in colorectal cancer. Mod Pathol
1994; 7: 161-5.
33. Nielsen GP, Jónasson JG, Agnarsson BA, ísaksson HJ.
Flow cytometric DNA analysis of adenocarcinomas of
the vermiform appendix. APMIS 1993; 101: 811—4.
34. Löfberg R, Broström O, Karlén P, Öst Á, Tribukait B.
DNA aneuploidy in ulcerative colitis: reproducibility,
topographic distribution and relation to dysplasia. Gas-
troenterology 1992; 102: 1149-54.
35. Jónasson JG, Hrafnkelsson J. Nuclear DNA analysis
and prognosis in carcinoma of the thyroid gland. A
nationwide study in Iceiand on carcinomas diagnosed
1955-1990. Virchows Archiv 1994; 425: 349-55.
36. Jeffers MD, O’Dwyer P, Curran B, Leader M, Gillan
JE. Partial hydatidiform mole: a common but underdi-
agnosed condition. A 3-year retrospective clinicopath-
ological and DNA flow cytometric analysis. Int J Gyn
Path 1993; 12: 315-22.
37. Lage JM, Popek EJ. The role of DNA flow cytometry in
evaluation of partial and complete hydatidiform moles
and hydropic abortions. Sem Diagn Pathol 1993; 10:
267-74.
38. Baldetorp B, Bendahl P-O, Fernö M, Alanen K, Delle
U, Falkmer U, et al. Reproducibility in DNA flow cyto-
metric analysis of breast cancer: comparison of 12 lab-
oratories’ results for 67 sample homogenates. Cytom-
etry 1995; 22: 115-27.